Qiagen NV's board has determined, after completing a strategic review, that the company's current stand-alone business plan "represents the best opportunity to drive future value creation."
The supervisory and management board of Netherlands-based Qiagen, which provides solutions for molecular testing for the diagnosis of diseases and the development of treatments, started discussions with interested parties to explore strategic alternatives to maximize shareholder value.
This process was announced in mid-November after Qiagen received several conditional, non-binding indications of interest for a full acquisition. Bloomberg News had reported earlier that Thermo Fisher Scientific Inc. reached out to Qiagen with a potential deal.
Qiagen's board decided that the alternatives to the stand-alone prospects were not compelling and has terminated all discussions so that the company's management can focus on executing the stand-alone plan.